【荣昌生物:2024年亏损14.68亿元】荣昌生物公告称,2024年度营业总收入为17.15亿元,同比增长58.40%。报告期内,公司实现归属于母公司所有者的净利润亏损14.68亿元。报告期末,公司总资产为549,914.78万元,归属于母公司的所有者权益为198,638.60万元。本年度公司新药研发管线持续推进,多个创新药物处于关键试验研究阶段,研发投入增加,预计公司2024年度为净亏损。

金融界
27 Feb
荣昌生物公告称,2024年度营业总收入为17.15亿元,同比增长58.40%。报告期内,公司实现归属于母公司所有者的净利润亏损14.68亿元。报告期末,公司总资产为549,914.78万元,归属于母公司的所有者权益为198,638.60万元。本年度公司新药研发管线持续推进,多个创新药物处于关键试验研究阶段,研发投入增加,预计公司2024年度为净亏损。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10